Turk Ilac ve Serum Sanayi AS
IST:TRILC.E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (3.3), the stock would be worth ₺22.68 (537% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | ₺3.56 |
0%
|
| 3-Year Average | 3.3 | ₺22.68 |
+537%
|
| Industry Average | 26.9 | ₺182.99 |
+5 040%
|
| Country Average | 10.6 | ₺72.14 |
+1 926%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| TR |
T
|
Turk Ilac ve Serum Sanayi AS
IST:TRILC.E
|
576m TRY | 0.5 | -0.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 49.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 22.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 19.3 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 14.4 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 16.5 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 12.9 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 8.3 | 16.6 |
Market Distribution
| Min | 1 |
| 30th Percentile | 5.3 |
| Median | 10.6 |
| 70th Percentile | 26.3 |
| Max | 2 793.6 |
Other Multiples
Turk Ilac ve Serum Sanayi AS
Glance View
Türk Ilaç ve Serum Sanayi AS engages in the manufacture of medical drugs. The main activity of the Company is to manufacture and sell all kinds of tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids and other chemical substances. The firm also acts as the representative or sales agency of other domestic and foreign pharmaceutical companies, as well as importing and marketing veterinary, cosmetics and pesticides. Turk Ilac manufactures in accordance with Current Good Manufacturing (GMP) and Good Laboratory Practice (GLP) principles with its approximately 300 employees in its facilities on a total area of 56.000 square meters in the Ankara - Akyurt region.
